ASCO 2022 Conference Coverage
Playback speed
10 seconds
ASCO 2022 Three-Year Outcomes and Correlative Analyses in Patients With NSCLC and a Very High PD-L1 Tumor Proportion Score ≥ 90% Treated With 1L Pembrolizumab
By
ASCO 2022 Conference Coverage
FEATURING
Biagio Ricciuti
By
ASCO 2022 Conference Coverage
FEATURING
Biagio Ricciuti
308 views
June 8, 2022
Login to view comments.
Click here to Login
Lung